Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LGBTQ+

- PMLiVE

NICE set to dismiss Millennium’s Crohn’s drug Entyvio

Body cites uncertain evidence and unlikely value for the NHS

- PMLiVE

Type 2 diabetes market in Asia-Pacific to hit $10.5bn by 2020

Analysts predict increase of $4bn from 2013 figure

- PMLiVE

Amgen and Kite in $1bn cancer immunotherapy tie up

Latest major research deal in growing area of oncology

Novartis day

FDA close to first biosimilar approval

US regulator’s advisory board recommends Novartis’ version of Amgen’s Neupogen

- PMLiVE

Blue Latitude boosts its team

Blue Latitude has appointed Ben Routley, Natalie Seebeck and Kasia Zygadlewicz to its team, following a series of new business wins and increased work from existing clients.

Blue Latitude Health

- PMLiVE

Janssen partners with Isis on stomach conditions

Will develop treatments that target RNA in people with autoimmune disorders

- PMLiVE

Huntsworth names Paul Taaffe as CEO

Former head of comms at Groupon will replace Lord Chadlington in April

- PMLiVE

Lilly names head of corporate business development

Promotion for Darren Carroll

- PMLiVE

Janssen and Gilead extend HIV collaboration

Will develop single tablet regimen that combines Prezista, Tybost, emtricitabine and tenofovir alafenamide

- PMLiVE

Organs-in-a-dish aid drug discovery

Using stem cells to generate complex tissues and organs in the lab is promising to tackle a key bottleneck in drug discovery

- PMLiVE

FDA approved 44 new drugs in 2014

AstraZeneca leads pharma success with four approvals, but Bayer had a year to forget  

- PMLiVE

NICE rejects pancreatic cancer regimen over cost concerns

Charity says draft decision to deny Abraxane/Gemzar combo is a ‘backwards step’ for the NHS pricing body

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links